A phase 1/2 first in human study of ADI-270, an armored allogeneic anti-CD70 chimeric antigen receptor γδ T cell therapy, in patients with relapsed or refractory clear cell renal cell carcinoma

ADI-270 - Adicet Bio

https://dx.doi.org/10.1136/jitc-2024-SITC2024.0640

Kathryn Beckermann1; Brian Rini2; Blake T Aftab3; Helen Budworth3; Francesco Galimi3; Shon Green4; Nadine Jahchan3; Jackie Kennedy-Wilde3; Kevin P Nishimoto3; Gregory S Vosganian3; Yining Ye3; Benjamin Garmezy5; Sumanta Pal6

Oct 4, 2024